Across TCGA pan-cancer cohorts, NHLRC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NHLRC2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NHLRC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NHLRC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NHLRC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.642	0.384	<.001	48	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	14	view →
LUAD	DFS	Tertile	II,III,IV	0.221	0.562	.006	12	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.198	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NHLRC2 tumor-vs-normal RNA expression · all NHLRC2 data types